TG Therapeutics
TGTX • NASDAQ
TG Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Michael S. Weiss, with a market cap of $5.1B.
CEOMichael S. Weiss
Next Earnings
Upcoming earnings announcement for TG Therapeutics
Date
Monday, May 4, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.28
Revenue Estimate
$198.6M
Earnings History
Past 12 earnings reports for TG Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Q4 2025 | $0.14Est: $0.34 | -58.8% | $192.6MEst: $191.8M | +0.4% |  10-K |
| Nov 3, 2025 | Q3 2025 | $2.43Est: $0.22 | +1004.5% | $161.7MEst: $151.6M | +6.7% | 10-Q |
| Aug 4, 2025 | Q2 2025 | $0.17Est: $0.30 | -43.3% | $141.1MEst: $142.2M | -0.7% | 10-Q |
| May 5, 2025 | Q1 2025 | $0.03Est: $0.17 | -82.4% | $120.9MEst: $117.9M | +2.5% | 10-Q |
| Mar 3, 2025 | Q4 2024 | $0.15Est: $0.08 | +87.5% | $108.2MEst: $98.5M | +9.8% | 10-K |
| Nov 4, 2024 | Q3 2024 | $0.02Est: $0.03 | -33.3% | $83.9MEst: $81.7M | +2.7% | 10-Q |
| Aug 6, 2024 | Q2 2024 | $0.04Est: -$0.05 | +180.0% | $73.5MEst: $65.9M | +11.5% | 10-Q |
| May 1, 2024 | Q1 2024 | -$0.07Est: -$0.04 | -75.0% | $63.5MEst: $54.6M | +16.3% | 10-Q |
| Feb 28, 2024 | Q4 2023 | -$0.09Est: -$0.10 | +10.0% | $44.0MEst: $40.1M | +9.8% | 10-K |
| Nov 1, 2023 | Q3 2023 | $0.73Est: $0.12 | +508.3% | $165.8MEst: $46.6M | +256.1% | — |
| Aug 1, 2023 | Q2 2023 | -$0.34Est: -$0.25 | -36.0% | $16.1MEst: $17.5M | -7.9% | — |
| May 1, 2023 | Q1 2023 | -$0.28Est: -$0.37 | +24.3% | $7.8MEst: $3.4M | +130.9% | — |